Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Open access
Czuczman, Myron S., Trněný, Marek, Davies, Andrew, Rule, Simon, Linton, Kim M., Wagner-Johnston, Nina, Gascoyne, Randy D., Slack, Graham W., Brousset, Pierre, Eberhard, David A., Hernandez-Ilizaliturri, Francisco J., Salles, Gilles, Witzig, Thomas E., Zinzani, Pier Luigi, Wright, George W., Staudt, Louis M., Yang, Yandan, Williams, P. Mickey, Lih, Chih-Jian, Russo, Jacqueline, Thakurta, Anjan, Hagner, Patrick, Fustier, Pierre, Song, Dale, Lewis, Ian D. · 2017 · Clinical Cancer Research

Abstract

Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Experimental Design: Patients with DLBCL who received ≥2 prior therapies were stratified by DLBCL subtype [germinal center B-cell (GCB) vs. non-GCB; determined by immunohistochemistry (IHC)] and then randomized 1:1 to lenalidomide (25 mg/day, 21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide, or oxaliplatin). Crossover to lenalidomide was permitted for IC-treated patients with radiologically confirmed progressive disease. The primary endpoint was overall response rate (ORR). Progression-free survival (PFS), overall survival, and subtype analysis [GCB vs. activated B-cell (ABC)] using gene expression profiling (GEP) were exploratory endpoints. Results: Stage 1: 102 DLBCL patients (by IHC: non-GCB, n = 54; GCB, n = 48) received ≥1 dose of lenalidomide or IC. Hematologic treatment-emergent adverse events with lenalidomide versus IC included neutropenia (42.6%; 36.4%), anemia (33.3%; 47.3%), thrombocytopenia (24.1%; 43.6%), and leukopenia (5.6%; 12.7%), respectively. Overall, lenalidomide-treated patients had an ORR of 27.5% versus 11.8% in IC (ORRs were similar regardless of IHC-defined DLBCL subtype). Median PFS was increased in patients receiving lenalidomide (13.6 weeks) versus IC (7.9 weeks; P = 0.041), with greater improvements in non-GCB patients (15.1 vs. 7.1 weeks, respectively; P = 0.021) compared with GCB (10.1 vs. 9.0 weeks, respectively; P = 0.550). Conclusions: The clinical benefit of lenalidomide monotherapy in DLBCL patients was more evident in the non-GCB subtype. Exploratory analyses suggest that this preferential benefit was more pronounced in the GEP-defined ABC population, demonstrating a need for additional studies of lenalidomide in DLBCL using GEP subtyping. Clin Cancer Res; 23(15); 4127–37. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2818

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 162

Metadata

Authors
Czuczman, M. S., Trněný, M., Davies, A., Rule, S., Linton, K. M., Wagner-Johnston, N., Gascoyne, R. D., Slack, G. W., Brousset, P., Eberhard, D. A., Hernandez-Ilizaliturri, F. J., Salles, G., Witzig, T. E., Zinzani, P. L., Wright, G. W., Staudt, L. M., Yang, Y., Williams, P. M., Lih, C.-J., Russo, J., Thakurta, A., Hagner, P., Fustier, P., Song, D., & Lewis, I. D.
Venue
Clinical Cancer Research
Published
2017-08-01
Volume
23
Issue
15
Pages
4127-4137
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2605009867
Cited by
162
References
2
FWCI
13.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2818
The paper
Czuczman, M. S., Trněný, M., Davies, A., Rule, S., Linton, K. M., Wagner-Johnston, N., Gascoyne, R. D., Slack, G. W., Brousset, P., Eberhard, D. A., Hernandez-Ilizaliturri, F. J., Salles, G., Witzig, T. E., Zinzani, P. L., Wright, G. W., Staudt, L. M., Yang, Y., Williams, P. M., Lih, C.-J., . . . Lewis, I. D. (2017). A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.